cMAST: A Customizable Platform for High-Throughput Translation Analysis
Transforming RNA Translation Research with Custom-Multiplex Solutions
In today’s competitive biotech and pharma landscape, researchers face mounting pressure to accelerate drug discovery and development while reducing costs. Traditional methods for studying RNA translation—such as ribosome profiling and reporter assays—are often time-consuming, expensive, and limited in scope. cMAST, EIRNA Bio’s proprietary platform that enables customized Multiplexed Assessment of Translation, revolutionizes translational biology research by enabling high-throughput, multi-parameter analysis of RNA translation in a cost-effective and scalable manner.
Why Investigate RNA Translation?
Understanding translation—the process by which mRNA is converted into functional proteins—is essential for unravelling disease mechanisms and identifying new drug targets. Dysregulation of translation is a hallmark of many diseases, including:
- Cancer
- Neurological disorders
- Metabolic diseases
- Aging-related conditions
Translation also plays a crucial role in drug target discovery, as many therapeutic interventions work by modulating translational control pathways. Accurately measuring translation provides a more precise assessment of drug efficacy and potential off-target effects.
Key Features of cMAST:
cMAST overcomes the limitations of conventional methods by offering:
- Massively Parallel Translation Analysis – Simultaneously assess translation of multiple genes, transcript regions, and RNA motifs in a single experiment.
- Customization for Specific Research Needs – Tailor the platform to focus on genes of interest, known off-targets, 5′ leaders, or RNA sequence motifs.
- High-Throughput Efficiency – Screen hundreds of experimental conditions at a fraction of the time and cost required for ribosome profiling or single-parameter reporter assays.
- Actionable Insights – Capture accurate measure of protein synthesis directly related to the parameter of interest.
Advantages of cMAST:
cMAST is more cost-effective than ribosome profiling for screening large numbers of experimental conditions (e.g., compound libraries, dose and time course experiments) and offers a faster, more insightful, and cost-effective alternative to reporter assays.
Applications of cMAST
cMAST is designed to accelerate drug discovery and therapeutic development by:
- Screening for small molecules that modulate translation
- Rapidly assess dose and time dependent effects of RNA-targeting therapeutics (ASOs, RNAi)
- Uncovering key translation-regulating pathways in disease
- Assessing compound effects on protein synthesis in real-time
Unlock the Power of Translation Research
By combining customization, scalability, and efficiency, cMAST provides an unparalleled solution for translational biology research. Whether you are exploring disease mechanisms, screening for new drugs, or validating RNA-targeting compounds, cMAST delivers deeper insights, faster.